Literature DB >> 28978463

Risk factors of occult malignancy in patients with unprovoked venous thromboembolism.

Philippe Robin1, Pierre-Yves Le Roux2, Cécile Tromeur3, Benjamin Planquette4, Nathalie Prévot-Bitot5, Christian Lavigne6, Jean Pastre4, Adel Merah7, Francis Couturaud3, Grégoire Le Gal8, Pierre-Yves Salaun9.   

Abstract

Venous thromboembolism (VTE) can occur as the first manifestation of an underlying occult malignancy. It remains unclear whether or not a better selection of high risk patients might lead to more efficient occult cancer screening strategies. Our aim was to assess the predictors of occult malignancy diagnosis in patients with unprovoked VTE. Univariate analyses were performed to assess the effect of candidate predictors on occult cancer detection in patients enrolled in a prospective, multicenter, randomized, controlled study (MVTEP study) whose primary aim was to compare a limited screening strategy with a strategy combining limited screening and FDG PET/CT in patients with unprovoked VTE. This trial is completed and registered with ClinicalTrials.gov, number NCT00964275. Between March 3, 2009, and August 18, 2012, 399 patients were included. Five patients withdrew consent and refused the use of their data, and no VTE was confirmed in 2 patients who were excluded from this analysis. A total of 25 (6.4%) out of the 392 analysed patients received a new diagnosis of malignancyduring the 2-years follow-up. Age≥50years (p=0.01), male gender (p=0.04), leukocytes count (p=0.01), and platelets count (p=0.03) were associated with occult cancer detection. Patients with leukocytosis or thrombocytosis had a risk of cancer way above 10%. Previous VTE and smoker status (combining previous and current smokers) were not associated with occult cancer diagnosis (p>0.05). Demographic characteristics (age and sex), and laboratory tests (high platelets and leukocytes counts) may be associated with cancer detection in patients withunprovoked VTE.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Occult cancer; Risk factor; Screening strategy; Unprovoked venous thromboembolism

Mesh:

Year:  2017        PMID: 28978463     DOI: 10.1016/j.thromres.2017.08.021

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.

Authors:  Lindsay Robertson; Cathryn Broderick; Su Ern Yeoh; Gerard Stansby
Journal:  Cochrane Database Syst Rev       Date:  2021-10-01

2.  Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.

Authors:  Lindsay Robertson; Su Ern Yeoh; Cathryn Broderick; Gerard Stansby; Roshan Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2018-11-08

Review 3.  Screening for Occult Cancer in Patients with Venous Thromboembolism.

Authors:  Julien D'Astous; Marc Carrier
Journal:  J Clin Med       Date:  2020-07-27       Impact factor: 4.241

4.  Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?

Authors:  Filipa Ferreira; José Pereira; Ana Lynce; José Nunes Marques; Ana Martins
Journal:  Cureus       Date:  2020-02-10

5.  Screening for cancer in unprovoked venous thromboembolism.

Authors:  Salma Shivji; Marc Carrier
Journal:  Hemasphere       Date:  2019-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.